The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 341:871-878 September 16, 1999 Number 12
NextNext

Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation
Peter J. Kudenchuk, M.D., Leonard A. Cobb, M.D., Michael K. Copass, M.D., Richard O. Cummins, M.D., Alidene M. Doherty, B.S.N., C.C.R.N., Carol E. Fahrenbruch, M.S.P.H., Alfred P. Hallstrom, Ph.D., William A. Murray, M.D., Michele Olsufka, B.S.N., and Thomas Walsh, M.I.C.P.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Whether antiarrhythmic drugs improve the rate of successful resuscitation after out-of-hospital cardiac arrest has not been determined in randomized clinical trials.

Methods We conducted a randomized, double-blind, placebo-controlled study of intravenous amiodarone in patients with out-of-hospital cardiac arrest. Patients who had cardiac arrest with ventricular fibrillation (or pulseless ventricular tachycardia) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to receive 300 mg of intravenous amiodarone (246 patients) or placebo (258 patients).

Results The treatment groups had similar clinical profiles. There was no significant difference between the amiodarone and placebo groups in the mean (±SD) duration of the resuscitation attempt (42±16 and 43±16 minutes, respectively), the number of shocks delivered (4±3 and 6±5), or the proportion of patients who required additional antiarrhythmic drugs after the administration of the study drug (66 percent and 73 percent). More patients in the amiodarone group than in the placebo group had hypotension (59 percent vs. 48 percent, P=0.04) or bradycardia (41 percent vs. 25 percent, P=0.004) after receiving the study drug. Recipients of amiodarone were more likely to survive to be admitted to the hospital (44 percent, vs. 34 percent of the placebo group; P=0.03). The benefit of amiodarone was consistent among all subgroups and at all times of drug administration. The adjusted odds ratio for survival to admission to the hospital in the amiodarone group as compared with the placebo group was 1.6 (95 percent confidence interval, 1.1 to 2.4; P=0.02). The trial did not have sufficient statistical power to detect differences in survival to hospital discharge, which differed only slightly between the two groups.

Conclusions In patients with out-of-hospital cardiac arrest due to refractory ventricular arrhythmias, treatment with amiodarone resulted in a higher rate of survival to hospital admission. Whether this benefit extends to survival to discharge from the hospital merits further investigation.


Source Information

From the Department of Medicine, Division of Cardiology (P.J.K., L.A.C., C.E.F., W.A.M., M.O.), the Department of Neurology (M.K.C.), the Department of Emergency Medicine (R.O.C., A.M.D.), and the Department of Biostatistics (A.P.H.), University of Washington; and the Seattle Fire Department (T.W.) — both in Seattle.

Address reprint requests to Dr. Kudenchuk at the Division of Cardiology, Box 356422, University of Washington, Seattle, WA 98195-6422.

Full Text of this Article


Related Letters:

Amiodarone in Out-of-Hospital Cardiac Arrest
Ballew K. A., Philbrick J. T., Kudenchuk P. J., Cobb L. A., Copass M. K.
Extract | Full Text  
N Engl J Med 2000; 342:216-217, Jan 20, 2000. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.